Brief: Apimeds Welcomes FDA Draft Guidance As Catalyst For Advancing Apitox Non-Opioid Pain Program
12/09/2025 02:55
Sept 11 (Reuters) - Apimeds Pharmaceuticals US Inc APUS.A: APIMEDS WELCOMES FDA DRAFT GUIDANCE AS CATALYST FOR ADVANCING APITOX NON-OPIOID PAIN PROGRAM APIMEDS PHARMACEUTICALS US INC - FDA GUIDANCE MAY ACCELERATE APIMEDS' APITOX PROGRAM Source text: ID:nBwlysdma Further company coverage: APUS.A ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Apimeds Pharmaceuticals US
See all newsBrief: Mindwave Innovations Signs 3 Client Network Agreements In 10 Days, Extending Mindchain Into Climate Finance, Sports Media And Insurance Apimeds Pharmaceuticals Us Provides Required NYSE American Disclosure
Brief: Apimeds Pharmaceuticals US Enters Assignment And Transfer Agreement With Freet On August 19
Brief: Apimeds Pharmaceuticals Us Inc Vin Menon Continues To Serve As The Company’S Chief Executive Officer
Brief: Apimeds Pharmaceuticals Appoints Youngjik Cho As Chairman Of Board
Brief: Apimeds Pharmaceuticals Us Inc. Announces Material Breach Of Merger Agreement By Inscobee Inc And Apimeds Inc